Videos

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, explains what the gut-brain axis is and how microbiome impacts this connection.

In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed the role of the microbiome in overall patient health and recurrent Clostridioides difficile infection.

Lodise said that one of the notable takeaways is the de-prioritization of polymyxins for the treatment of these infections.

In this video, Dr. Sherman describes the pharmacology and pharmacokinetics of cabotegravir and rilpivirine as long acting injectable antiretroviral therapy agents.

In this video, Dr. Sherman describes what pre-exposure prophylaxis is and how long-acting injectable antiretroviral agents can help to prevent HIV and may even improve adherence.

Lodise discussed key points from the guidance, current regimen recommendations, and clinical scenarios where therapy recommendations outside of the guidelines might be considered.

Rivaroxaban and apixaban are the most commonly prescribed direct oral anticoagulants, although they may be most effective in different populations.

Lodise discussed key points from the guidance, current regimen recommendations, and clinical scenarios where therapy recommendations outside of the guidelines might be considered.

Patients ages 80 and older have unique considerations when deciding whether to initiate anticoagulation therapy.

In part 2 of the discussion, Lodise said the decision of which drugs to use for various infections is very nuanced, but the new guidance document utilized the best available evidence.

Thomas Lodise, PharmD, PhD, discussed new guidance released by the Infectious Diseases Society of America (IDSA) on the treatment of antimicrobial resistant gram-negative infections.

Experts review the impact that medications, antibiotic or otherwise, may have on the development of Clostridioides difficile infection.

Panelists look at the class effects of BTK inhibitors and share optimal strategies to select therapy and manage toxicities.

An overview of the risk factors that contribute to the development of Clostridioides difficile infection in various health care settings.

Expert perspectives on the MAGNOLIA trial and novel BTK inhibitor zanubrutinib in the context of marginal zone lymphoma treatment.

Nakia Eldridge, PharmD, MPH, senior manager of health care quality, safety, and information at US Pharmacopeia (USP), and Lindsey Clawson, MBA, USP’s lead of COVID-19 vaccine strategy, discuss the latest updates in USP’s COVID-19 Vaccine Handling Toolkit.

Myfembree controls heavy menstrual bleeding due to uterine fibroids in premenopausal women.

Jamie L. McConaha, PharmD, NCTTP, BCACP, CDE, considers the benefit of over-the-counter options for battling atopic dermatitis, such as the topical products CeraVe and Eucerin.

A panel of experts discusses diabetes treatment management and the impact pharmacists can have on an increasingly diverse patient population.

Parathyroid hormone (Natpara) is indicated to control hypocalcemia in patients with hypoparathyroidism.

Debra Goff, PharmD, FIDSA, FCCP, infectious diseases specialist at the Ohio State University Wexner Medical Center, discusses Clostridioides difficile awareness and potential future treatments.

Comprehensive discussion on the identification of Clostridioides difficile infection, the spectrum of disease, and overall epidemiology.

A broad review of BTK inhibition as a novel therapeutic approach toward the treatment of marginal zone lymphoma.

The panel reflects on how disruption of the gut microbiome leads to the proliferation of Clostridioides difficile.

Following discussion on the NCCN guidelines for second-line therapy in marginal zone lymphoma, experts highlight approved treatment options.

Ray Tancredi, RPh, MBA, divisional VP of specialty pharmacy development and brand Rx/vaccine purchasing at Walgreens, provides an analysis and overview of key specialty pharmaceuticals in development.

Ismail Lourido Ali, the director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses continuing education opportunities for pharmacists to get trained on the proper use and administration of psychedelic drugs.

Ron Aung-Din, MD, the clinical medical advisor of Pyscheceutical, and Chad Harman, the CEO of Pyscheceutical, discuss a novel approach for administering psychedelics for the treatment of brain disorders that does not induce hallucinogenic effects.

Ray Tancredi, RPh, MBA, divisional VP of specialty pharmacy development and brand Rx/vaccine purchasing at Walgreens, discusses key drugs in development that are slated to launch in 2022.